Navigation Links
Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.

PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH). The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

"We are pleased that work with this research program has led to its expansion and excited that a global biopharmaceutical company of Cephalon's stature is increasingly interested in the potential of our technologies," said Scott Jackson, chief executive officer, Celator Pharmaceuticals.  "Because our nano-scale delivery platforms have already been shown to improve the pharmacokinetics and antitumor activity of several cancer therapies, we are eager to collaborate with companies like Cephalon with growing oncology portfolios and an established commitment to improving treatment outcomes."

Terms and conditions of the research agreement are confidential.

Celator is advancing a number of its own programs based on the Company's proprietary nano-scale delivery platforms.  The Company recently announced positive topline results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy in untreated acute myeloid leukemia, including a statistically significant improvement in complete remission rate and a reduction in 30-day and 60-day mortality.  CPX-351 is one of a pipeline of investigational cancer therapies developed using Celator's CombiPlex® drug-ratio technology. Celator also has an agreement with the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL) whereby the NCL selected the Company's hydrophobic docetaxel prodrug nanoparticle formulation for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols to support an eventual investigational new drug (IND) filing with the U.S. Food and Drug Administration.

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at  

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at Information on ongoing trials is available at

SOURCE Celator Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
2. Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference
3. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
4. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
5. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
6. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
7. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
8. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
9. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
10. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
11. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case of mesothelioma ... signs of mesothelioma and push for a diagnosis, especially in people exposed to asbestos. ... here to read it now. , Researchers at Gifu Prefectural Tajimi Hospital ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may ... one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there ... save the expense of having to replace NuvaRings more often than necessary. As such, ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
Breaking Medicine News(10 mins):